Drug intelligence / Profile preview

NXL-007

Development stage: Preclinical
Lead developer: NeuExcell Therapeutics
Modality: Gene Therapies

Overview

**NXL-007** is an investigational gene therapy developed by NeuExCell Therapeutics, Inc., utilizing adeno-associated virus (AAV) vector-mediated gene transference, likely involving the NeuroD1 transcription factor for in situ conversion of glioblastoma cells into neuron-like cells. It represents a novel approach to treat glioblastoma by reprogramming tumor cells rather than killing them, aiming to halt tumor progression. Currently in preclinical development, it marks a pioneering effort in AAV-NeuroD1 gene therapy for this aggressive brain cancer.[9][10][14]

Beyond the preview

Go deeper on NXL-007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NXL-007.

Explore the full profile